A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
3.
CANCER INTERVENTION BY TARGETING GENOTYPIC DIFFERENCES USING CRISPR-CAS3 MEDIATED DELETION-EDITING
Provided are compositions and methods for selectively killing cancer cells. The method includes obtaining one or more biological samples from an individual, determining different nucleotide sequences in cancer and non-cancer cells from the biological sample using an algorithm to identify a candidate target sequence that is present in the cancer cells and not present in the non-cancer cells. Based on the different nucleotide sequences in the cancer cells relative to the non-cancer cells a CRISPR Cas3 system that includes a guide RNA targeted to an identified segment of the chromosome that is linked to the target sequence is degraded.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Disclosed is a method of treating or alleviating a symptom of a cancer in a subject, comprising sequentially administering to the subject a combination of a thymidine analogue and a PARP inhibitor, followed by administration of a G2-kinase inhibiting drug.
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids of SEQ ID NO:1 and one or more adjuvant. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition
Provided are methods for treating cancer. The methods involve administering to an individual who has cancer a combination of peptidase D (PEPD), a sheddase inhibitor, a chemotherapeutic agent and a coagulation inhibitor.
Provided is method of detecting SARS-CoV-2 in a sample, including amplifying polynucleotides in the sample to form subgenomic amplicons using a forward subgenomic primer and a reverse subgenomic primer, wherein the forward subgenomic primer hybridizes to a forward subgenomic primer target of a subgenomic SARS-CoV-2 N protein transcript or its complement and the reverse subgenomic primer hybridizes to a reverse subgenomic primer target of the subgenomic SARS-CoV-2 transcript or its complement, and detecting an amount of hybridization of a subgenomic SARS-CoV-2 transcript probe to the subgenomic amplicons, wherein the subgenomic SARS-CoV-2 transcript probe hybridizes to a probe target of the subgenomic amplicons, wherein the probe target of the subgenomic amplicons includes at least a portion of a leader sequence, a transcriptional regulatory sequence, and at least a portion of a junction region between the transcriptional regulatory sequence and a coding sequence of the subgenomic SARS-CoV-2 transcript and the probe target is between the forward subgenomic primer target and the reverse subgenomic primer target
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
Provided are modified cells and methods for their use in treating cancer. The cells are modified to express and secrete a Bi-specific T cell engager (BiTE) that includes a segment that specifically binds to human Folate Receptor alpha (FRα) and a segment that that specifically binds to human CD3, such as CD3e. The modified cells can be T cells. Methods for producing the modified cells are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
Provided is a method for treating an individual for a programmed-death 1 (PD-1) immune checkpoint therapy resistant cancer. The method involves administering to the individual a combination of a Toll-like receptor 3 (TLR3) agonist and interferon-alpha (IFNα), followed by close in time administration of an anti-PD-1 immunotherapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
10.
METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS
Provided are methods for therapy or prophylaxis of genotoxic stress. The methods include administering to an individual in need an effective amount of Matrix Metalloproteinase (MMP)-9. The individual in need may have or be at risk of developing Acute Radiation Syndrome (ARS), or may have received or is receiving chemotherapy, or has insufficient hematopoietic function. The present disclosure provides results from a mouse model of lethal ARS induced by TBI to demonstrate that neutrophils (N) are essential mediators of the radiomitigative but not radioprotective abilities of entolimod, express functional TLR5 butundergo minimal transcriptional changes post-entolimod suggesting that N mitigate 30 ARS through a transcriptional-independent mechanism; and increase the number of active hematopoietic B pluripotent precursors (HPPs) in bone marrow.
Disclosed is a method of treating or alleviating a symptom of a cancer in a subject, comprising sequentially administering to the subject TAS-102 followed by a BCL-2 inhibitor.
Provided are methods for treatment of survivin-positive autoimmune diseases comprising administration of survivin specific antibodies to subjects who are afflicted with an autoimmune disease.
H. Lee Moffitt Cancer Center and Research Institute, Inc. (USA)
Inventor
Kalinski, Pawel
Czerniecki, Brian
Abstract
Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A device includes a first fiber lock configured to be attached to a handle of an EUS-NA device and to selectively lock or unlock a fiber optic cable in position with respect to a sample needle. A second fiber lock is configured to be attached to abase of the EUS-NA device and to selectively lock or unlock a fiber optic cable in position. A method includes passing a fiber optic cable through a passage of the EUS-NA device such that an end of the fiber optic cable is at a tip of a sample needle of the EUS-NA device. The fiber optic cable is locked relative to the sample needle, and the sample need is advanced into the target tissue. The fiber optic cable is unlocked from the sample needle and locked relative to abase of the EUS-NA device. The sample needle is retracted such that the end of the fiber optic cable remains in the target tissue.
Provided are compositions and methods that relate to therapy of B cell diseases and include discovery of novel molecular heterogeneity of the signaling component (i.e., CD79) of human B cell antigen receptor (BCR). The method includes co-administering antibodies or antigen binding fragments thereof that specifically bind CD79a and CD79b to provide synergistic therapy of B cell tumors. The method may further include administering an antibody that specifically binds to an immune checkpoint molecule, such as programmed cell death protein 1 (PD-1).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
19.
ANTIPROLIFERATIVE BETTI BASES AND PRODRUGS THEREOF
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
HEALTH RESEARCH, INC. (USA)
Inventor
Wang, Xinjiang
Chemler, Sherry R.
Lama, Rati
Galster, Samuel
Abstract
Provided are compounds with the structure: Also provided are compositions of the compound. The compounds have broad anti¬ proliferative activity against cancer cells, including leukemia, pancreatic cancer, and melanomas. Also provided are methods for inhibiting the growth of cells and/or inducing apoptosis and/or ferroptosis.
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 213/16 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 215/28 - AlcoholsEthers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
22.
LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX
A container is provided for securing IV medication during use. The container includes a housing with a removable cover. The housing has an internal volume for placement of IV medication. In other words, the housing and the cover form an internal volume when the container is closed. The container has a biometric lock for selectively locking the cover to the housing. The biometric lock may be a fingerprint lock. The biometric lock may be configured to store an access log. In another aspect, a method for securing IV medication during use is provided.
Provided are methods for prophylaxis and therapy for viral infections. The methods can facilitate a synergistic anti-viral effect. The method involves administering a combination of agents to an individual in need thereof. The combinations of agents are selected from interferons (IFNs), Toll-Like Receptor (TLR) ligands, polyinosinic:polycytidylic acid, rintatolimod, tumor necrosis factor alpha (TNF-a) or an inducer thereof, and nuclear factor kappa B (NF-xB) or an inducer or activator thereof.
The present disclosure relates to a fluid treatment apparatus. The fluid treatment apparatus includes a first system for removing one or more target compounds from a fluid, said first system comprising adsorbent particles; a second system for regenerating said adsorbent particles; a first connector between said first system and said second system, said first connector configured to transfer adsorbent particles from said first system to said second system; and a second connector between said first system and said second system, said second connector configured to release of adsorbent particles from said second system, wherein said first system and said second system are decoupled. The present disclosure further relates to a system comprising one or more fluid treatment apparatus described herein. Also described herein are methods for treating fluid and a system comprising the methods for treating fluid described herein.
B01D 15/02 - Separating processes involving the treatment of liquids with solid sorbentsApparatus therefor with moving adsorbents
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
C02F 1/28 - Treatment of water, waste water, or sewage by sorption
C02F 1/32 - Treatment of water, waste water, or sewage by irradiation with ultraviolet light
C02F 1/36 - Treatment of water, waste water, or sewage with mechanical oscillations ultrasonic vibrations
B01J 20/08 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group comprising aluminium oxide or hydroxideSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group comprising bauxite
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
C02F 1/70 - Treatment of water, waste water, or sewage by reduction
The present disclosure provides methods for treating an individual in need of a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.
The present disclosure provides methods for treating an individual in need of a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07C 233/81 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
C07D 271/113 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 239/74 - QuinazolinesHydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
C07D 239/70 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
C07C 49/643 - Unsaturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system having three rings
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
C07C 281/08 - Compounds containing any of the groups e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
C07D 327/08 - [b, e]-condensed with two six-membered carbocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
27.
METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMA
Provided are methods for treating individuals suspected of having or having Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) associated cancer via administration of a CPSF3 inhibitor. Such cancers include pancreatic ductal adenocarcinoma (PDAC). The CPSF3 inhibitor may further attenuate PDAC cell proliferation and colony formation. The CPSF3 inhibitor may be JTE-607, which has the following structure:
Provided are methods for treating individuals suspected of having or having Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) associated cancer via administration of a CPSF3 inhibitor. Such cancers include pancreatic ductal adenocarcinoma (PDAC). The CPSF3 inhibitor may further attenuate PDAC cell proliferation and colony formation. The CPSF3 inhibitor may be JTE-607, which has the following structure:
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
28.
METHODS AND SYSTEMS FOR OPTIMIZING VOLUMETRIC MODULATED ARC THERAPY (VMAT) TREATMENT PLANS
A volumetric modulated arc therapy (VMAT) treatment plan may be optimized by obtaining a VMAT treatment plan and calculating a radiation dose matrix corresponding to each a plurality of beamlets, wherein each beamlet represents a change in field when an MLC leaf is moved a predetermined unit distance. The method includes defining an enhanced objective function (EOF) for achieving one or more clinical objectives and minimizing the EOF for proposed leaf positions iterating through each leaf of at least a subset of the leaves of the VMAT treatment plan (wherein the proposed leaf positions move each leaf into the field or out of the field by the predetermined unit distance and correspond to the addition or subtraction of the corresponding radiation dose matrix). The set of leaf positions of the VMAT treatment plan is updated according to the proposed leaf positions of the minimized EOF.
Provided are modified cells and methods for their use in treating cancer. The cells are modified to express and secrete a Bi-specific T cell engager (BiTE) that includes a segment that specifically binds to human Folate Receptor alpha (FRα) and a segment that that specifically binds to human CD3, such as CD3e. The modified cells can be T cells. Methods for producing the modified cells are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The Board of Regents of the University of Texas System (USA)
Inventor
Li, Hongmin
Li, Zhong
Zhou, Jia
Xu, Jimin
Abstract
The present disclosure relates to a Prp8 intein splicing inhibitor. The present disclosure further relates to a method of treating and/or preventing a fungal infection, said method comprising administering a Prp8 intein splicing inhibitor under conditions effective to treat and/or prevent a fungal infection. Also disclosed is a method of inhibiting Prp8 intein expression or activity in a cell or tissue, said method comprising administering a compound under conditions effective to inhibit Prp8 intein expression or activity in a cell or tissue. Further disclosed are methods for screening for compounds that inhibit Prp8 intein splicing comprising an assay and a kit for predicting the likelihood of Prp8 inhibition.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to an individual in need of treatment inhibitors of WHSC1 expression, function or activity in combination with PARP inhibitors or immune based therapy. In an aspect, the present disclosure provides compositions comprising one or more WHSC1 inhibitors and one or more PARP inhibitors, or one or more WHSC1 inhibitors and one or more immune checkpoint inhibitors.
A device for automatic suturing includes a shaft having a longitudinal axis. The shaft has a joint rotatable about a joint axis which is at an angle>0° to the longitudinal axis. The device includes a clamp at a distal end of the shaft. The clamp is configured to be positioned over a length of tissue to be sutured. A driver is configured to engage with a screw of the shaft so that the driver translates along a length of the shaft when the driver is rotated. A helical needle is connected to the driver such that rotation of the driver causes rotation of the helical needle. In this way, the needle is advanced or retracted over a length of the clamp and over the joint of the shaft.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
33.
CANCER INTERVENTION BY TARGETING GENOTYPIC DIFFERENCES USING CRISPR-CAS3 MEDIATED DELETION-EDITING
Provided are compositions and methods for selectively killing cancer cells. The method includes obtaining one or more biological samples from an individual, determining different nucleotide sequences in cancer and non-cancer cells from the biological sample using an algorithm to identify a candidate target sequence that is present in the cancer cells and not present in the non-cancer cells. Based on the different nucleotide sequences in the cancer cells relative to the non-cancer cells a CRISPR Cas3 system that includes a guide RNA targeted to an identified segment of the chromosome that is linked to the target sequence is degraded.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure provides a method and a system for treating a tissue using photodynamic therapy (PDT). A photosensitizer is administered to the tissue and one or more optical fibers are placed in the tissue. A treatment light is applied to the tissue by way of the one or more optical fibers. A temperature of the tissue is measured during application of the treatment light, and a fluence rate of the treatment light is modified based on the temperature of the tissue. For example, the fluence rate may be modified to be lower if the temperature of the tissue is higher than a predetermined threshold.
G01K 7/36 - Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat using magnetic elements, e.g. magnets, coils
35.
DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER
Provided are methods for treating cancer. The methods involve administering to an individual who has cancer a combination of peptidase D (PEPD), a sheddase inhibitor, a chemotherapeutic agent and a coagulation inhibitor.
The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
37.
COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS AGAINST CLAUDIN 6
Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a Claudin 6 (CLDN6) antigen. Included are recombinant T cell receptors (TCRs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including CD4+ T cells, CD8+ T cells, and progenitor cells, such as hematopoietic stem cells. The modified cells are capable of direct and indirect recognition of a cancer ell expressing a CLDN6 antigen by human leukocyte antigen (HLA) class I and II restricted binding of the TCR to the CLDN6 antigen expressed by the cancer cell, with or without presentation of the antigen by antigen presenting cells. Also included is a method for prophylaxis and/or therapy of cancer by administering modified cells that express a recombinant TCR that binds to CLDN6.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/02 - Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
38.
PHARMACEUTICAL COMPOSITIONS WITH ANTIFLAVIVIRAL ACTIVITY
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (USA)
Inventor
Li, Hongmin
Kramer, Laura D.
Li, Zhong
Huang, Ruili
Xia, Menghang
Abstract
Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
DUKE UNIVERSITY (USA)
Inventor
Vare, Ville
Mcdonough, Kathleen
Schneider, Ryan
Agris, Paul
Seyler, Thorsten
Abstract
Provided is a method for inhibiting the growth of Gram-positive bacteria, including contacting said bacteria with a first compound and a second compound, wherein the first compound is a compound of Formula I:
and the second compound is an antibiotic other than a compound of Formula I. Also provided is a composition including the first compound and the second compound.
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
Provided are methods for therapy or prophylaxis of genotoxic stress. The methods include administering to an individual in need an effective amount of Matrix Metalloproteinase (MMP)-9. The individual in need may have or be at risk of developing Acute Radiation Syndrome (ARS), or may have received or is receiving chemotherapy, or has insufficient hematopoietic function. The present disclosure provides results from a mouse model of lethal ARS induced by TBI to demonstrate that neutrophils (N ) are essential mediators of the radiomitigative but not radioprotective abilities of entolimod, express functional TLR5 but undergo minimal transcriptional changes post-entolimod suggesting that N mitigate 30 ARS through a transcriptional-independent mechanism; and increase the number of active hematopoietic pluripotent precursors (HPPs) in bone marrow.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
Inventor
Kalinski, Pawel
Czerniecki, Brian
Abstract
Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.
Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
43.
REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD)
Provided are methods for prophylaxis or therapy of cancer. The methods are directed to cancers that are characterized by expression of a mutant p53. The mutant p53 may be a loss of function p53 mutant, dominant negative p53 mutant, or a gain of function p53 mutant. The method comprises delivering to cancer cells an agent that can inhibit expression of prolidase (PEPD) or disrupts the association of mutant p53 with PEPD.
A device includes a first fiber lock configured to be attached to a handle of an EUS-NA device and to selectively lock or unlock a fiber optic cable in position with respect to a sample needle. A second fiber lock is configured to be attached to a base of the EUS-NA device and to selectively lock or unlock a fiber optic cable in position. A method includes passing a fiber optic cable through a passage of the EUS-NA device such that an end of the fiber optic cable is at a tip of a sample needle of the EUS-NA device. The fiber optic cable is locked relative to the sample needle, and the sample need is advanced into the target tissue. The fiber optic cable is unlocked from the sample needle and locked relative to a base of the EUS-NA device. The sample needle is retracted such that the end of the fiber optic cable remains in the target tissue.
A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
In some embodiments, an apparatus for implantable therapy includes a power supply and a first implantable component. The power supply includes a transmitter configured to provide a first signal at a first frequency. The power supply also includes a receiver configured to receive a second signal at a harmonic of the first frequency. The first implantable component includes an LC circuit configured to resonate at the first frequency. One or more light-emitting diodes (LEDs) of the first implantable component are configured to be powered by the first signal received at the LC circuit. In this way, powering the one or more LEDs forms a harmonic of the first signal (e.g., a third harmonic of the first signal). In some embodiments, the apparatus include a second implantable component with a sensor, which may be a light sensor.
Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Provided are compositions, methods, and devices for reducing scarring during healing of a tissue wound. The compositions and methods involve use of sphingosine-1-phosphate (S1P), and/or an expression vector that encodes sphingosine kinase1 (SphK1). The compositions can be combined with other agents and implements, such as biocompatible nanoparticles, and medical devices involved with promoting wound healing. The approaches can reduce formation or prevent the occurrence of keloids.
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure relates to a method for assessing color vision. The method includes identifying one or more steady-state visual evoked potentials (SSVEPs) to identify metamers. The present disclosure further relates to devices for assessing color vision that use metamers identified via steady-state visual evoked potentials (SSVEPs). Also disclosed herein are methods of treating color vision deficiency, systems for identifying a response to one or more metameric stimuli, methods of individually modifying color vision, methods for assessing color vision using neural activity as a means to personalize visual displays, and methods for assessing light sensitive cells in the nervous system using flashing lights.
A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing light sensitivity, e.g. adaptationSubjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and/or hyperplastic cells and/or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and/or hyperplastic cell growth and/or molecular imaging of malignant cells and/or hyperplastic cells and/or inducing degradation of a target protein. Also provided are compositions.
A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
52.
ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES
Provided are methods for treatment of survivin-positive autoimmune diseases comprising administration of survivin specific antibodies to subjects who are afflicted with an autoimmune disease.
The Research Foundation for The State University of New York (USA)
Inventor
Pandey, Ravindra K.
Dukh, Mykhaylo
Marko, Aimee
Sajjad, Munawwar
Abstract
Compounds for tumor imaging (e g , magnetic resonance (MR) and fluorescence) that may be used in combination with other methods to treat an individual having or suspected of having cancer (e.g., various forms of cancer, such as, for example, solid tumors). Compounds may have the following structure: (I) or a salt, a partial salt, a hydrate, a polymorph, an isomer (e.g., a structural or stereoisomer), or a mixture thereof, where R′ is an aryl group or heteroaryl group having a halogen group (e.g., I or 124I), X is chosen from O, S, or NH, n is 1-6 (e.g., 1, 2, 3, 4, 5, or 6), the dotted carbon is chiral and is R or S.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
A nebulizer for medicament is provided. The nebulizer includes a cup having an interior surface. An axle is attached to the cup at least at a location along a central axis of the cup such that rotation of the axle causes a rotation of the cup about the central axis. A fan is operably attached to the axle and configured to generate a flow of air adjacent to the cup. A drum is disposed around a circumference of the cup, and configured to contain the generated flow of air near the cup. A conduit is configured to receive liquid medicament and deposit such medicament on a surface of the cup.
The present disclosure relates to a fluid treatment apparatus. The fluid treatment apparatus includes a first system for removing one or more target compounds from a fluid, said first system comprising adsorbent particles; a second system for regenerating said adsorbent particles; a first connector between said first system and said second system, said first connector configured to transfer adsorbent particles from said first system to said second system; and a second connector between said first system and said second system, said second connector configured to release of adsorbent particles from said second system, wherein said first system and said second system are decoupled. The present disclosure further relates to a system comprising one or more fluid treatment apparatus described herein. Also described herein are methods for treating fluid and a system comprising the methods for treating fluid described herein.
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/04 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
56.
COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
C07D 253/065 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
57.
METHODS FOR DISRUPTING MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE
The present disclosure provides methods for treating an individual in need of treatment of conditions in which HSP60/ClpP expression and/or binding is abnormal with a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.
To induce cancer cell death, cancer cells are selected that express estrogen-receptor β (ERβ) and mutant tumor protein 53 (TP53). An agent that increases ERβ protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERβ and mutant TP53, an agent that increases ERβ protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor β (ERβ) expression levels in a subject having low ERβ expression levels, tamoxifen is administered to increase ERβ protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor β (ERβ) and wildtype tumor protein 53 (TP53), an agent that inhibits ERβ and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.
An apparatus for identifying and quantifying image distortions within a patient magnetic resonance image set comprises a structure of magnetic resonance compatible materials with a high level of rigidity, where the structure is configured to cover the whole image volume of the brain region of the patient and sized to fit within a brain magnetic resonance coil when worn by a patient. A plurality of magnetic resonance fiducial markers is placed on the structure, thereby permitting the measurement of three-dimensional distances between the markers when the patient undergoes a magnetic resonance imaging procedure. Also presented is a process for identifying and quantifying image distortions within a patient magnetic resonance image set using the apparatus where the geometrical distortion is quantified and compared with a set threshold or a standard image.
Disclosed herein are novel anti-microbial peptides with inhibitory activity against M. tuberculosis and streptococcus bacteria. Additionally, a method for designing novel anti-microbial peptides is disclosed.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
Provided are methods for prophylaxis and therapy for viral infections. The methods can facilitate a synergistic anti-viral effect. The method involves administering a combination of agents to an individual in need thereof. The combinations of agents are selected from interferons (IFNs), Toll-Like Receptor (TLR) ligands, polyinosinic:polycytidylic acid, rintatolimod, tumor necrosis factor alpha (TNF-α) or an inducer thereof, and nuclear factor kappa B (NF-ϰB) or an inducer or activator thereof.
Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension. Also provided is a kit containing reagents and compositions for performing the foregoing method.
A method for treating prostate cancer in a subject involves selecting a subject having prostate cancer and cytochrome c-deficiency, and administering, to the selected subject, a therapeutically effective amount of one or more agents capable of restoring cytochrome-c activity. Also presented is a method of inducing apoptosis in drug resistant cancer cells involving selecting drug resistant cancer cells having cytochrome-c deficiency, and administering to the selected cells, one or more agents that restore cytochrome-c activity in an amount effective to sensitize said cancer cells to drug induced apoptosis. A combination therapeutic comprising one or more agents increases cytochrome-c activity and efficacy of a chemotherapeutic agent. Another method involves selecting a subject having cancer, and obtaining a cell sample including tumor tissues/biopsy and blood samples from said subject, and further involves measuring cytochrome-c expression levels and Drp1 phosphorylation levels in said sample.
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A volumetric modulated arc therapy (VMAT) treatment plan may be optimized by obtaining a VMAT treatment plan and calculating a radiation dose matrix corresponding to each a plurality of beamlets, wherein each beamlet represents a change in field when an MLC leaf is moved a predetermined unit distance. The method includes defining an enhanced objective function (EOF) for achieving one or more clinical objectives and minimizing the EOF for proposed leaf positions iterating through each leaf of at least a subset of the leaves of the VMAT treatment plan (wherein the proposed leaf positions move each leaf into the field or out of the field by the predetermined unit distance and correspond to the addition or subtraction of the corresponding radiation dose matrix). The set of leaf positions of the VMAT treatment plan is updated according to the proposed leaf positions of the minimized EOF.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventor
Li, Hongmin
Li, Zhong
Zhou, Jia
Xu, Jimin
Zhang, Qing-Yu
Abstract
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07C 233/75 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
C07D 211/46 - Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
66.
Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen
+ T cells, natural killer T cells, γδ T cells, and progenitor cells, such as haematopoietic stem cells. The modified cells are capable of direct recognition of a cancer cell expressing a NY-ESO-1 antigen by human leukocyte antigen (HLA) class II-restricted binding of the TCR to the NY-ESO-1 antigen expressed by the cancer cell without presentation of the antigen by antigen presenting cells. In embodiments, the NY-ESO-1 antigen is displayed by the tumor cells. Also included is a method for prophylaxis and/or therapy of cancer by administering modified cells that express a recombinant TCR. Methods for making expression vectors and/or cells which express a recombinant TCR and identifying TCRs to make the expression vectors are also included.
A composition including an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor can be used in therapy or as a medicament. The composition including the anti-CD123 antibody-drug conjugate and the poly ADP ribose (PARP) inhibitor can be used for treating cancer or for inducing cancer cell death in a population of cancer cells. Hematological cancers such as acute myeloid leukemia (AML) can be treated with the composition. Administering an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method of treating cancer. Administering, to a population of cancer cells, an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method for inducing cancer cell death.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61P 35/02 - Antineoplastic agents specific for leukemia
68.
COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventor
Li, Hongmin
Li, Zhong
Zhou, Jia
Xu, Jimin
Abstract
The present disclosure relates to a Prp8 intein splicing inhibitor. The present disclosure further relates to a method of treating and/or preventing a fungal infection, said method comprising administering a Prp8 intein splicing inhibitor under conditions effective to treat and/or prevent a fungal infection. Also disclosed is a method of inhibiting Prp8 intein expression or activity in a cell or tissue, said method comprising administering a compound under conditions effective to inhibit Prp8 intein expression or activity in a cell or tissue. Further disclosed are methods for screening for compounds that inhibit Prp8 intein splicing comprising an assay and a kit for predicting the likelihood of Prp8 inhibition.
A device for automatic suturing includes a shaft having a longitudinal axis. The shaft has a joint rotatable about a joint axis which is at an angle > 0° to the longitudinal axis. The device includes a clamp at a distal end of the shaft. The clamp is configured to be positioned over a length of tissue to be sutured. A driver is configured to engage with a screw of the shaft so that the driver translates along a length of the shaft when the driver is rotated. A helical needle is connected to the driver such that rotation of the driver causes rotation of the helical needle. In this way, the needle is advanced or retracted over a length of the clamp and over the joint of the shaft.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/03 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith
A61B 17/06 - NeedlesHolders or packages for needles or suture materials
Georgia State University Research Foundation, Inc. (USA)
Inventor
Ionov, Yurij
Srivastava, Pramod
Mandoiu, Ion
Zelikovsky, Alex
Abstract
Provided are methods for identifying antigens containing amino acid sequences for use in a cancer vaccine. The vaccines and methods of use for prophylaxis and/or therapy of cancer are included. The method involves: i) exposing cancer cells to a chemotherapeutic agent that damages DNA; ii) determining open reading frames encoded by mRNA transcribed from a gene in the cancer cells of i); iii) comparing the open reading frames of the mRNA of i) to open reading frames encoded by mRNA transcribed from the gene in the cancer cells that were not exposed to the chemotherapeutic agent, iv) determining a different open reading frame encoded by the mRNA of i) and an open reading frame of the mRNA of ii), wherein the different open reading frame encoded by the mRNA of i) encodes a contiguous amino acid sequence comprising the sequence of the antigen for use in the cancer vaccine.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
Modified eukaryotic cells that contain a DNA sequence comprising a drug inducible Cre-recombinase expression system, a sequence encoding a Cas9 enzyme, and a conditional promoter that becomes operably linked to the sequence encoding the Cas9 enzyme by function of the Cre-recombinase system, are provided. The disclosure further provides compositions comprising the modified cells and methods of administering the modified cells to an individual in need thereof.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Provided is a method for mapping a neural area involved in speech processing, including applying a plurality of recording electrodes to a surface of a cortex of a human subject, presenting a plurality of auditory stimuli to the subject wherein some of the plurality of stimuli are speech sounds and others of the plurality of auditory stimuli are non-speech sounds, recording brain activity during the presenting of the plurality of auditory stimuli, and identifying one or more brain areas wherein activity changes more after presentation of speech sounds than it does after presentation of non-speech sounds, wherein the human subject does not speak during the presenting and the recording. Also provided is a method for mapping a neural area involved in speech production wherein the human subject does not speak during presenting speech stimuli and recording neural activity.
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
74.
MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-EXPRESSING CANCER CELL VACCINE AND METHODS OF USE FOR PRODUCING INTEGRATED IMMUNE RESPONSES
Provided are modified cancer cells that are modified to co-express class II trans-activator (CIITA), and an immuno-stimulatory molecule. The immuno-stimulatory molecule is OX-40-ligand or 4-1BB-Ligand. Methods of making the cells are provided by introducing polynucleotides encoding the CIITA and the immune-stimulatory molecule into cancer cells. Methods of stimulating humoral and cell-mediated immune responses by administering the modified cancer cells, or polynucleotides encoding the CIITA and immune-stimulatory molecules are also provided. These approaches can be used to stimulate an immune response against any of a wide variety of cancer antigens.
A method of inhibiting activity or expression of one or more 3α-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT. The method comprises introducing one or more agents into cells that comprise the one or more 3α-oxidoreductase enzymes, wherein said one or more agents: i) inhibit function of one or more of said enzymes; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
76.
COMBINATION OF BETA-ADRENERGIC RECEPTOR ANTAGONISTS AND CHECK POINT INHIBITORS FOR IMPROVED EFFICACY AGAINST CANCER
Provided are methods for prophylaxis and/or therapy of cancer that include administering to an individual in need thereof an effective amount of a β-blocker and an immune checkpoint inhibitor such that growth of cancer in the individual is inhibited. Patients include those diagnosed with or at risk for a wide variety of cancer types. Methods are provided for cancer treatment in individuals who are resistant to checkpoint inhibitor monotherapies. Greater than additive anti-cancer effects may be achieved.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 35/04 - Antineoplastic agents specific for metastasis
77.
COMPOSITIONS AND METHODS RELATED TO OVERCOMING INNATE IMMUNE BARRIERS TO CANCER IMMUNOTHERAPY
Provided are methods for identifying and treating individuals who have cancer, and also have immunosuppressive neutrophils. The method of treating includes administering one or more drugs that inhibit formation of immunosuppressive neutrophils. Cancer patients can be identified, and selected for treatment, based on a positive result obtained by exposing a biological sample from the patient to normal neutrophils, and subsequently exposing the neutrophils to T cells, and measuring activation of T the cells. Reduced activation of the T cells relative to a control provides an indication that the individual has the immunosuppressive neutrophils, and is a candidate to receive the drug. The drug administered to the cancer patient functions to inhibit SNARE-dependent exocytosis, or inhibits NADPH oxidase, or inhibits complement signaling. The method further includes administering to the individual an immune checkpoint inhibitor, which may increase the efficacy of the checkpoint inhibitor.
Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to an individual in need of treatment inhibitors of WHSC1 expression, function or activity in combination with PARP inhibitors or immune based therapy. In an aspect, the present disclosure provides compositions comprising one or more WHSC1 inhibitors and one or more PARP inhibitors, or one or more WHSC1 inhibitors and one or more immune checkpoint inhibitors.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
80.
REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD)
Provided are methods for prophylaxis or therapy of cancer. The methods are directed to cancers that are characterized by expression of a mutant p53. The mutant p53 may be a loss of function p53 mutant, dominant negative p53 mutant, or a gain of function p53 mutant. The method comprises delivering to cancer cells an agent that can inhibit expression of prolidase (PEPD) or disrupts the association of mutant p53 with PEPD.
Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided.
A method of treating an inflammatory disease or disorder is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-15. The inflammatory disease is not cancer, osteoporosis, rheumatic arthritis, osteoarthritis or angiogenesis-related eye disease.
A spacer for an inhaler includes a housing defining a chamber. The housing has an ambient port in fluid communication with ambient air, an inhaler port configured for attachment of an inhaler, and an outlet. The spacer further includes a fan for generating a flow of air through the chamber from the ambient port to the outlet. The fan may be powered by way of a spring such that the fan generates the flow of air as stored energy is released from a spring. Embodiments of the spacer may have an actuator for triggering a release of stored energy from the spring thereby actuating the fan. A mask or mouthpiece may be provided at the outlet.
The methods and assays described herein relate to detection, diagnosis, and treatment of aberrant immune system activity (e.g., in bronchial premaglinant lesions), e.g., by detecting the level of expression of certain immune regulators described herein and/or by therapeutically modulating the level of those immune regulators.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and/or hyperplastic cells and/or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and/or hyperplastic cell growth and/or molecular imaging of malignant cells and/or hyperplastic cells and/or inducing degradation of a target protein. Also provided are compositions.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
C07J 17/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta[a]hydrophenanthrene skeleton
C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventor
Pandey, Ravindra, K.
Dukh, Mykhaylo
Marko, Aimee
Sajjad, Munawwar
Abstract
Compounds for tumor imaging (e.g., magnetic resonance (MR) and fluorescence) that may be used in combination with other methods to treat an individual having or suspected of having cancer (e.g., various forms of cancer, such as, for example, solid tumors). Compounds may have the following structure: (I) or a salt, a partial salt, a hydrate, a polymorph, an isomer (e.g., a structural or stereoisomer), or a mixture thereof, where R' is an aryl group or heteroaryl group having a halogen group (e.g., I or 124I), X is chosen from O, S, or NH, n is 1-6 (e.g., 1, 2, 3, 4, 5, or 6), the dotted carbon is chiral and is R or S.
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
89.
MEDICINAL NEBULIZER AND METHOD OF DISPENSING MEDICAMENT
A nebulizer for medicament is provided. The nebulizer includes a cup having an interior surface. An axle is attached to the cup at least at a location along a central axis of the cup such that rotation of the axle causes a rotation of the cup about the central axis. A fan is operably attached to the axle and configured to generate a flow of air adjacent to the cup. A drum is disposed around a circumference of the cup, and configured to contain the generated flow of air near the cup. A conduit is configured to receive liquid medicament and deposit such medicament on a surface of the cup.
The present disclosure may be embodied as an incontinence device for a catheterized individual. The device includes an absorbent pad configured to be worn by the individual. The absorbent pad having a slit partially separating the pad into two portions. A fastener may be provided for selectively attaching the two portions to each other. In this way, a catheter may be disposed through the slit of the device and the two portions may be attached to each other using the fastener to surround a circumference of the catheter. The fastener may be reusable. In some embodiments, the device includes more than one fastener. The fastener may be one or more of an adhesive, a hook-and-loop fastener, a snap fastener, or combinations thereof.
An apparatus for identifying and quantifying image distortions within a patient magnetic resonance image set comprises a structure of magnetic resonance compatible materials with a high level of rigidity, where the structure is configured to cover the whole image volume of the brain region of the patient and sized to fit within a brain magnetic resonance coil when worn by a patient. A plurality of magnetic resonance fiducial markers is placed on the structure, thereby permitting the measurement of three-dimensional distances between the markers when the patient undergoes a magnetic resonance imaging procedure. Also presented is a process for identifying and quantifying image distortions within a patient magnetic resonance image set using the apparatus where the geometrical distortion is quantified and compared with a set threshold or a standard image.
A method for treating prostate cancer in a subject involves selecting a subject having prostate cancer and cytochrome c-deficiency, and administering, to the selected subject, a therapeutically effective amount of one or more agents capable of restoring cytochrome-c activity. Also presented is a method of inducing apoptosis in drug resistant cancer cells involving selecting drug resistant cancer cells having cytochrome-c deficiency, and administering to the selected cells, one or more agents that restore cytochrome-c activity in an amount effective to sensitize said cancer cells to drug induced apoptosis. A combination therapeutic comprising one or more agents increases cytochrome-c activity and efficacy of a chemotherapeutic agent. Another method involves selecting a subject having cancer, and obtaining a cell sample including tumor tissues/biopsy and blood samples from said subject, and further involves measuring cytochrome-c expression levels and Drp1 phosphorylation levels in said sample.
To induce cancer cell death, cancer cells are selected that express estrogen-receptor β (ERβ) and mutant tumor protein 53 (TP53). An agent that increases ERβ protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERβ and mutant TP53, an agent that increases ERβ protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor β (ERβ) expression levels in a subject having low ERβ expression levels, tamoxifen is administered to increase ERβ protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor β (ERβ) and wildtype tumor protein 53 (TP53), an agent that inhibits ERβ and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.
A composition comprising an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor can be used in therapy or as a medicament. The composition comprising the anti-CD123 antibody-drug conjugate and the poly ADP ribose (PARP) inhibitor can be used for treating cancer or for inducing cancer cell death in a population of cancer cells. Hematological cancers such as acute myeloid leukemia (AML) can be treated with the composition. Methods for treating cancer comprise administering to a subject an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor. Methods for inducing cancer cell death comprise administering, to a population of cancer cells, an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor.
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
Ionov, Yurij
Srivastava, Pramod
Mandoiu, Ion
Zelikovsky, Alex
Abstract
Provided are methods for identifying antigens containing amino acid sequences for use in a cancer vaccine. The vaccines and methods of use for prophylaxis and/or therapy of cancer are included. The method involves: i) exposing cancer cells to a chemotherapeutic agent that damages DNA; ii) determining open reading frames encoded by mRNA transcribed from a gene in the cancer cells of i); iii) comparing the open reading frames of the mRNA of i) to open reading frames encoded by mRNA transcribed from the gene in the cancer cells that were not exposed to the chemotherapeutic agent, iv) determining a different open reading frame encoded by the mRNA of i) and an open reading frame of the mRNA of ii), wherein the different open reading frame encoded by the mRNA of i) encodes a contiguous amino acid sequence comprising the sequence of the antigen for use in the cancer vaccine.
A method includes engaging a clamp over a length of tissue to be sutured. A helical needle is advanced along a length of the clamp such that the helical needle passes through the tissue to be sutured. A leading end of a suturing thread is attached at a tip of the helical needle. The leading end of the suturing thread is captured. The helical needle is retracted back through the tissue so as to leave the thread in place. The clamp is disengaged from the tissue. A device for automatic suturing includes a clamp configured to be positioned over a length of tissues to be sutured. A helical needle is configured to be advanced and retracted along a length of the clamp. The needle has a tip. A suturing thread having a leading end is attached to the tip of the helical needle.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
Linear accelerator (“linac”) downtime invariably impacts delivery of patients' scheduled treatments. Transferring a patient's treatment to an available linac is a common practice. Transferring a VMAT plan from a linac equipped with a standard-definition MLC to one equipped with a higher definition MLC is practical and routine in clinics with multiple MLC-equipped linacs. However, the reverse transfer presents a challenge because the high-definition MLC aperture shapes must be adapted for delivery with the lower definition device. An efficient method to adapt VMAT plans originally designed for a high-definition MLC to a standard definition MLC is disclosed herein. The dosimetric results of the present adaptation method are presented for head-and-neck, brain, lung and prostate VMAT plans. The delivery of the adapted plans was verified using standard phantom measurements.
Compounds including a tetrapyrrolic or reduced tetrapyrrolic group/moiety and an epidermal growth factor receptor targeting group are disclosed. For example, a compound includes a tetrapyrrolic or reduced tetrapyrrolic group or moiety, a linker moiety, an epidermal growth factor receptor targeting group, and, optionally, a PET-active functional group. Uses of the compounds, for example, methods of treating a hyperproliferative tissue in an individual, and kits including one or more of the compounds are also provided.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
100.
METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION
The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.
